Salah Hamed Mohamed Mohamed, Mahmoud Alaa, Rashdan Haitham Thabit Abd Alkareem, Mousa Elshimaa A Mateen
Department of Ophthalmology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Sci Rep. 2025 Aug 19;15(1):30330. doi: 10.1038/s41598-025-16065-7.
Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment. This cross-sectional study was conducted on 40 female patients aged ≥ 18 who received treatment for BC. Patients were allocated to two groups: Group A served as the control group and did not receive AIs, while Group B received one of the AIs for BC treatment. Before treatment, there was no significant difference in tear break-up time (TBUT), Schirmer test (ST) score, and hexagonality. However, post-treatment TBUT and ST values were lower in Patients who received treatment. Corneal thickness, CCT, or back and front elevations were comparable before or after treatment. AI therapy in estrogen-dependent BC patients is associated with significant corneal changes, including potential corneal stress evidenced by impaired tear film function and reduced endothelial hexagonality, while corneal thickness and front and back elevation remain stable.
芳香化酶抑制剂（AI）疗法是雌激素受体阳性乳腺癌（BC）的首选治疗方法。虽然AI能有效抑制肿瘤生长，但雌激素剥夺可能会对眼睛产生负面影响。这项研究评估了激素治疗后雌激素依赖性乳腺癌患者眼前节的变化。这项横断面研究对40名年龄≥18岁且接受过乳腺癌治疗的女性患者进行。患者被分为两组：A组作为对照组，未接受AI治疗，而B组接受一种用于乳腺癌治疗的AI。治疗前，泪膜破裂时间（TBUT）、泪液分泌试验（ST）评分和六边形细胞比例无显著差异。然而，接受治疗的患者治疗后的TBUT和ST值较低。治疗前后角膜厚度、中央角膜厚度（CCT）或前后表面高度相当。雌激素依赖性乳腺癌患者接受AI治疗与显著的角膜变化有关，包括泪膜功能受损和内皮六边形细胞比例降低所证明的潜在角膜应激，而角膜厚度以及前后表面高度保持稳定。
